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OBJECTIVES: InApril 2005, theFoodandDrugAdministration (FDA) issuedablackbox
warning (BBW) regarding the risks of using atypical antipsychotics (AAPs) for behav-
ioral disorders in elderly patients with dementia. The objective of the present study
was to investigate the impact of the BBW on the utilization of non-antipsychotic psy-
chotropic drugs (NAPDs) such as benzodiazepines, anticonvulsants, antidepressants,
and anti-dementia agents in non-institutionalized dementia population.METHODS:
Medical Expenditure Panel Surveys, from year 2004 through 2007, were used in this
study. Utilization rates of NAPDs pre-warning (2004-2005) and post-warning (2006-
2007) were tracked over a four-year time period for both the main sample and Medi-
care cohorts. Chi-Square tests andmultivariate logistic regression analyses were per-
formed to examinepre-post differences inutilization rates (definedas elderly patients
taking at least one medication associated with dementia) and gain insights into pat-
terns of NAPD use with respect to demographic, insurance and other factors.
RESULTS: NAPD use increased in the post-warning period for the main sample as
well as the Medicare sample during the time period covered. The increase, however,
was not statistically significant. Multivariate logistic regression in the main sample
showed a greater likelihood of individuals receiving anti-dementiamedications (Odds
Ratio, OR 1.976, p 0.0195) and benzodiazepines (OR3.046, p 0.0227) in the post-
warning period as compared to the pre-warning period. Similarly, dementia patients
had a greater likelihood of receiving anti-dementiamedications (OR 2.229, p0.0065)
in the post-warning period as compared to the pre-warning period in the Medicare
sample as well. CONCLUSIONS: The regulatory warnings and labeling changes re-
garding off-label use of atypical antipsychotics in dementia treatment might have
resulted in spillover compensatory shift in the use of NAPD in non-institutionalized
populations.
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OBJECTIVES: Extra-pyramidal symptoms (EPS) can be a treatment emergent adverse
event associated with the use of atypical antipsychotics (AAPs). Studies assessing the
economic burden of EPS in schizophrenia are scarce.This study aims to assess health
care resource use and costs associated with EPS in patients with schizophrenia using
Medicaid data METHODS: A retrospective analysis of Marketscan Medicaid Multi-
State Database (2004-2009) was conducted. Patientswith a diagnosis of schizophrenia
andnewly initiatedonAAPwere included. The indexdatewas thedateof thefirstAAP
prescription fill. Two cohorts were created based on the presence or absence of either
a diagnosis code for EPS or a prescription claim for a known medication to treat EPS
during the90dayspost-index. PatientswithEPSwerematched topatientswithoutEPS
using propensity scores. The number of hospitalizations, emergency room (ER) and
associated health care costs were assessed in the 12 months follow up. Regression
models were conducted to compare utilization and costs between the two groups.
RESULTS:Total sample sizewas 4602.Of those, 545 (11.8%) had EPS. Younger age (36.6
vs. 38.9 years, p0.0001), higher proportion of African American patients (58.9% vs.
55.4%, p0.03), and a higher rate of risperidone use as the index treatment (61.1% vs.
36.1%, p0.0001) were observed in the EPS group. After matching, baseline covariates
were similar betweengroups. Patientswith EPShada significantly higher likelihoodof
schizophrenia-related (OR1.62, 95%CI1.18-2.23, p0.003) and all cause hospitaliza-
tions (OR1.45, 95% CI1.12-1.88, p0.0042) compared to patients without EPS. The
difference in schizophrenia-specific total health care, hospitalization, and prescrip-
tion drug costs between patients with and without EPS was $2636 (95% CI$1270-
$4002), $1427 (95% CI$467-2388), and $860 (95% CI$480-$1239), respectively.
CONCLUSIONS: The presence of EPS in patients with schizophrenia is associated
with increased health care resource utilization and higher direct medical costs.
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OBJECTIVES: Major depressive disorder (MDD) is frequently debilitating. The
American Psychiatric Association recommends adjunctive atypical antipsychotics
(AA) as a treatment option when response to antidepressants is inadequate. This
study compared medical costs and hospitalizations among MDD patients treated
with FDA-approved adjunctive AA. METHODS: This retrospective analysis used
medical and pharmacy claims data and enrollment information from a large US
health plan. Subjects were adult commercial enrollees with depression (ICD-9-CM
296.2x, 296.3x, 296.82, 300.4, 311) augmenting antidepressant therapy with an AA
(aripiprazole, olanzapine, or quetiapine) from 1/1/2004-1/31/2010. Subjects were
continuously enrolled for 6-month pre- and 12-month post-augmentation periods.
Those with schizophrenia or bipolar disorder were excluded. Post-augmentation
outcomes were all-cause and mental health (MH-) related medical costs and hos-
pitalizations. Costs and hospitalizations were modeled with generalized linear
models (gamma distribution, log link) and logistic regression, respectively. Regres-
sions controlled for dose, demographics, and general andMH-related health status.
Outpatient pharmacy costs were not assessed. RESULTS: 10,292 subjects were
identified across AA cohorts: aripiprazole, n3,849; olanzapine, n1,033; and que-
tiapine, n5,410. Mean age was 44.111.6 years and 70.3%were female. Compared
with the aripiprazole cohort, regression results showed that the olanzapine cohort
had higher predicted all-cause (1.22, p0.004) and MH-related (1.33, p0.002) med-
ical cost ratios and higher odds of all-cause (1.58, p0.001) and MH-related (1.81,
p0.001) hospitalizations. The quetiapine cohort also had higher predicted all-
cause (1.27, p0.001) and MH-related (1.23, p0.001) medical cost ratios and higher
odds of all-cause (1.65, p0.001) and MH-related (1.78, p0.001) hospitalizations.
Mean predicted all-cause andMH-relatedmedical costs, respectively, were $11,401
and $2,495 for aripiprazole, $13,905 and $3,316 for olanzapine, and $14,513 and
$3,072 for quetiapine. CONCLUSIONS: Compared with adjunctive olanzapine or
quetiapine, adjunctive aripiprazole was associated with lower mean all-cause and
MH-related medical costs and with lower odds of all-cause and MH-related hospi-
talizations in patients with depression.
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OBJECTIVES: A conspiracy between Mylan Laboratories and its active-ingredient
suppliers during the late 1990s resulted in the exit of manufacturers from the
lorazepammarket and a collusive price increase. The objectives were to 1) analyze
the market structure for lorazepam before and after the conspiracy; 2) measure
lorazepam prices before and after the conspiracy; and 3) estimate the social cost of
the conspiracy.METHODS: Data sources were the Medicaid State Drug Utilization
Data maintained by the Centers for Medicare & Medicaid Services (CMS) and the
First DataBank®National Drug File. The four-firmconcentration ratio (CR4) and the
Herfindahl-Hirschman index (HHI) for the Medicaid lorazepam market were mea-
sured from 1991 through 2009. Average quarterly per-claim pharmacy reimburse-
ment, as a proxy for average drug price, was computed. Average wholesale prices
(AWPs) for specific drug formswere obtained fromFirst DataBank®. Three separate
methodswere used to estimate overallMedicaid and social cost. RESULTS:CR4 and
HHI rose from 53 and 906, respectively, in 1991 to 87 and 2234 in 2009. In 1997, the
average spending per generic lorazepamprescription byMedicaidwas $7.00; it was
$30.24 in 1999. In 2009, spending per prescription was $8.48. AWPs for 3 common
dosage forms jumped identically for 8 firms on February 18, 1998. The estimated
total (12-year) cost of the conspiracy to Medicaid ranged from $613.7 - $713.5 mil-
lion (2009 $); and, overall for society, from$4.9 - $5.7 billion (2009 $).CONCLUSIONS:
Not all generic markets offer competitive prices. The lorazepam conspiracy was
very costly to Medicaid and other payers. This study has policy implications for
antitrust authorities aswell as physicians and payerswhoneed to have available to
them solid comparative-effectiveness research to justify the use of substitute
drugs in case of collusive pricing behavior in a single market such as lorazepam.
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OBJECTIVES: To evaluate the association of entries of generics/product-line exten-
sions and approval for clinical indications other than depression [such as general-
ized /social anxiety disorders (GAD/SAD)] with change in price-per-prescription of
brand selective-serotonin-reuptake-inhibitors (SSRIs) in the Texas Medicaid
program.METHODS: Utilization and expenditure variables from the Texas Medic-
aid summary database (1991-2009) were used. Price-per-prescription of a brand
SSRI for a given quarter was calculated as total expenditure (amount reimbursed)
divided by utilization (number of prescriptions dispensed). Two specifications of
autoregressive models were used with log-transformed price-per-prescription of a
brand SSRI as a ratio of current-to-previous quarter as the dependent variable. In
the first specification, generic entry of a brand SSRI was indicated by a dummy
variable. In the second specification, generic entry was measured by two continu-
ous variables - time to generic entry and time after generic entry. In both specifi-
cations, each of the events indicating entries of generics/product-line extensions
and approval for GAD and SADwere indicated by dummy variables. RESULTS: The
entry of sertraline was found to be positively associated (p0.05) with change in
price-per-prescription in both specifications of the Paxil® model. Time to patent
expiry was positively associated (p0.001) with change in price-per-prescription in
the Celexa® model. No other events were statistically significant. CONCLUSIONS:
Entries of generics/product-line extensions and approval for new clinical indica-
tions were not associated with change in price-per-prescription for a majority of
brand SSRIs. Promotional strategies indicating market entries of new product-line
extensions and facets of usage other than depression may be useful in controlling
the reimbursement of SSRI brands.
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OBJECTIVES: The illicit production of methamphetamine from the precursor
chemical pseudoephedrine (PSE) in domestic clandestine laboratories fuels a sig-
nificant portion of the domestic methamphetamine supply. Although states and
the federal government have taken steps to control access to PSE, it continues to be
available as a non-prescription drug in all but two states. The purpose of this
project was to assess the relationship between PSE sales and indicators of meth-
amphetamine use, specifically methamphetamine-related hospital admissions, in
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